TY  - JOUR 
AU  - Creedon, Helen
AU  - Balderstone, Lucy A.
AU  - Muir, Morwenna
AU  - Balla, Jozef
AU  - Gómez Cuadrado, Laura
AU  - Tracey, Natasha
AU  - Loane, Joseph
AU  - Kilnowska, Teresa
AU  - Muller, William J.
AU  - Brunton, Valerie G.
PY  - 2016
SN  - 1754-8403
UR  - http://hdl.handle.net/10259/9791
AB  - Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies presents a major clinical problem. Although preclinical studies have identified a number of possible mechanisms, clinical validation has been difficult. This is most...
LA  - eng
PB  - The Company of Biologists
KW  - HER2
KW  - Breast cancer
KW  - Resistance
KW  - Epithelial-to-mesenchymal transition
KW  - Salud
KW  - Health
KW  - Oncología
KW  - Oncology
KW  - Medicina
KW  - Medicine
TI  - Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer
DO  - 10.1242/dmm.023143
T2  - Disease Models & Mechanisms
VL  - 9
M2  - 131
ER  -